华兰生物(002007.SZ)：参股公司收到药品注册受理通知书

Core Viewpoint - The company Hualan Biological (002007.SZ) announced that its subsidiary, Hualan Ankang Biological Co., Ltd., has received a notice of acceptance for the application for the production registration of Adalimumab injection from the National Medical Products Administration of China [1] Group 1: Company Developments - Hualan Ankang is developing Adalimumab injection as a biosimilar drug [1] - The original product was developed by AbbVie and has been approved for marketing in multiple countries and regions worldwide [1] - Adalimumab is used to treat various immune diseases, including rheumatoid arthritis, ankylosing spondylitis, and psoriasis, with its efficacy and safety widely validated in clinical settings [1]